janssen vaccine sold brand name vaccine developed janssen vaccines leiden belgian parent company janssen subsidiary american company johnson viral vector vaccine based human adenovirus modified contain gene making spike protein virus causes bodys immune system responds spike protein produce vaccine requires one dose need stored clinical trials vaccine started june phase iii involving around january janssen announced days completed vaccination vaccine effective onedose regimen preventing symptomatic efficacy preventing severe efficacy preventing hospitalization death caused vaccine granted emergency use authorization eua us food drug administration conditional marketing authorization european medicines agency uk medicines healthcare products regulatory june fda revoked emergency use authorization janssen vaccine request cases thrombosis thrombocytopenia syndrome guillainbarré syndrome reported receipt janssen vaccine us centers disease control prevention cdc recommends preferential use mrna vaccines janssen vaccine including primary booster doses administered prevent persons aged years age older janssen vaccine may considered situations including persons contraindication receipt mrna february johnson johnson announced temporarily suspended production vaccine though also noted likely resume point future honor preexisting contracts oblige janssen supply vaccine using millions already existing vaccine doses inventory janssen vaccine used provide protection infection virus order prevent people aged eighteen years vaccine given intramuscular injection deltoid muscle initial course consists single evidence second booster dose needed prevent severe disease healthy october us centers disease control prevention cdc began recommending booster vaccine generally considered effective estimate lower limit confidence efficacy closely related effectiveness generally expected slowly decrease october janssen reported meeting us food drug administration vaccines related biological products advisory committee vrbpac single dose produced durable protection severe disease hospitalization least months united states even delta emerged also global decrease protection moderate disease attributed emerging variants outside us janssen also reported booster dose given months primary dose increased efficacy symptomatic disease ci globally us also increased efficacy severe disease nearly vaccine consists replicationincompetent recombinant adenovirus type viral vector expressing severe acute respiratory syndrome coronavirus spike protein stabilized cell line derived human embryonic retinal cells used production replication adenovirus similar approach used vaccine russian sputnik v use human embryonic kidney hek cells adenovirus vector viral vector lacks gene required replication therefore replicate human vaccine contains following excipients citric acid monohydrate trisodium citrate dihydrate ethanol alcohol hydroxypropyl betadex polysorbate sodium chloride sodium hydroxide hydrochloric unpunctured vials may stored twelve vaccine remain viable months standard stored april johnson johnson entered partnership catalent provide largescale manufacturing johnson johnson vaccine catalents bloomington indiana july partnership expanded include catalents facility anagni september grand river aseptic manufacturing agreed johnson johnson support manufacture vaccine including technology transfer fill finish manufacture grand rapids michigan december johnson johnson reig jofre spanish pharmaceutical company entered agreement manufacture vaccine reig jofres barcelona february sanofi johnson johnson struck deal sanofi provide support infrastructure sanofis marcylétoile france facility manufacture approximately twelve million doses johnson johnson vaccine per month march johnson johnson aspen pharmacare made deal manufacture million vaccines aspens gqeberha facility eastern cape south africa plan distribute vaccine countries mainly africa also vaccines global access covax march merck co johnson johnson struck deal merck manufacture johnson johnson vaccine two facilities united states help expand manufacturing capacity vaccine using provisions defense production month human error plant run emergent biosolutions baltimore resulted spoilage fifteen million doses johnson johnson vaccine error caught doses left plant delayed expected shipments johnson johnson vaccine within united error involved combining ingredients johnson johnson vaccine astrazeneca vaccine biden administration gave control plant johnson johnson said plant produce johnson johnson vaccine avoid july fda authorized emergent resume production distribution janssen million doses review vaccine adverse events reporting system vaers safety monitoring data us centers disease control prevention cdc april time million doses janssen vaccine administered showed reported reactions vaccine receipt nonserious consistent preauthorization clinical trials common side effects vaccine trials usually mild moderate occurred within two days vaccination got better within common side effects pain injection site headache tiredness muscle pain nausea affecting people coughing joint pain fever chills redness swelling injection site occurred less sneezing tremor throat pain rash sweating muscle weakness pain arms legs backache weakness feeling generally unwell occurred less rare side effects occurred less people hypersensitivity allergy itchy increased risk rare potentially fatal thrombosis thrombocytopenia syndrome tts associated mainly younger female recipients syndrome marked formation blood clots blood vessels combination low levels blood platelets days vaccines administration occurred rate per million vaccinated women aged years old occurs rarely populations ie women years older men allergic reactions including anaphylaxis occur rare cases within minutes one hour receiving may million doses administered cdc reported four cases anaphylaxis vaccination none resulted death cases cerebral venous sinus thrombosis three resulted july us fact sheet vaccine updated indicate may increased risk guillainbarré syndrome days following european medicines agency ema listed guillainbarré syndrome gbs rare side effect vaccine janssen added warning product august pharmacovigilance risk assessment committee prac recommended updating product information european medicines agency ema cases dizziness tinnitus ringing noises one ears linked administration vaccine tinnitus later labeled rare final safety study december cdc accepted recommendation panel experts preference using pfizerbionech moderna vaccines janssen vaccine due rare serious blood clotting may fda limited use janssen vaccine eighteen unable access vaccines otherwise medically ineligible vaccine stabilized version spike protein includes two mutations regular amino acids replaced prolines developed researchers national institute allergy infectious diseases vaccine research center university texas pandemic johnson johnson committed billion toward development notforprofit vaccine partnership biomedical advanced research development authority barda office assistant secretary preparedness response aspr us department health human services johnson johnson said vaccine project would notforprofit level company viewed fastest best way find collaborations world make november johnson johnson announced janssen would commit million barda would commit million fund ensemble johnson johnson subsidiary janssen vaccines partnership beth israel deaconess medical center bidmc responsible developing vaccine candidate based technology used make ebola preclinical trials indicated vaccine effectively protected hamsters rhesus macaques june johnson johnson national institute allergy infectious diseases niaid confirmed planned start clinical trials vaccine september possibility phase human clinical trials starting accelerated pace second half phase clinical trial started recruitment first subject july enrolled study participants belgium interim results phase trial established safety reactogenicity immunogenicity one dose days vaccine ensured ninety percent participants enough antibodies required neutralize virus days number reached one hundred percent viral particles high dose provided increase neutralizingantibody titers compared low dose second dose days first dose among participants ages years incidence grade solicited systemic adverse events much lower first immunization lowdose highdose groups finding contrasts observations respect messenger vaccines second dose associated increased substudy participants found humoral cellmediated immune responses including cytotoxic cells lasted least medical source phase iii clinical trial called ensemble started enrollment september completed enrollment december designed randomized doubleblind placebocontrolled clinical trial intended evaluate safety efficacy singledose vaccine versus placebo adults aged years age older study participants received single intramuscular injection dose level virus particles day trial paused october volunteer became company said found evidence vaccine caused illness announced october would resume january janssen announced safety efficacy data interim analysis ensemble trial data demonstrated vaccine effective preventing combined endpoints moderate severe days postvaccination among volunteers interim analysis based cases symptomatic among adult volunteers argentina brazil chile colombia mexico peru south africa united states deaths related reported vaccine group five deaths placebo group related trial anaphylaxis observed second phase iii clinical trial called ensemble started enrollment november ensemble differed ensemble study participants received two intramuscular im injections one day next day early results indicated efficacy severecritical plasma participants showed greater neutralization activity delta variant beginning december clinical trial vaccine candidate undergoing rolling review process committee medicinal products human use european medicines agency ema step expedite ema consideration expected conditional marketing february janssen applied ema conditional marketing authorization european commission approved vaccine janssen march finland janssen vaccine offered aged february janssen biotech applied us food drug administration fda emergency use authorization eua fda announced vaccines related biological products advisory committee vrbpac would meet february consider february ahead vrbpac meeting briefing documents janssen fda issued fda document recommends granting eua concluding results clinical trials safety data consistent fda eua guidance february meeting vrbpac voted unanimously recommend eua vaccine fda granted eua vaccine following february advisory committee immunization practices acip centers disease control prevention cdc recommended use vaccine aged april cdc fda issued joint statement recommending use janssen vaccine suspended due reports six cases cerebral venous sinus rare severe blood combination low levels blood platelets thrombocytopenia six women ages received symptoms occurred days received vaccination reported one woman died second woman hospitalized critical april fda cdc determined recommended pause regarding use janssen vaccine us lifted use vaccine eua fact sheets updated reflect risks thrombosisthrombocytopenia syndrome fda granted emergency use authorization cdc issued standing order use june fda revoked emergency use authorization janssen vaccine request february saint vincent grenadines issued emergency authorization janssen vaccine well moderna vaccine vaccine gamcovidvac vaccine sputnik v december johnson johnson entered agreement principle gavi vaccine alliance support covax facility february johnson johnson submitted formal request data package world health organization emergency use listing eul eul requirement participation covax johnson johnson anticipated providing five hundred million doses world health organization issued eul janssen vaccine vaccine march february vaccine received emergency authorization south april south africa suspended rollout program resumed april february bahrain authorized vaccine emergency february south korean ministry food drug safety began review johnson johnsons application approval late november johnson johnson submitted rolling review application health canada approval march vaccine received emergency authorization march vaccine authorized interim order april australian government stated would purchasing janssen vaccine intend purchase adenovirus vaccines therapeutic goods administration granted provisional approval use janssen vaccine australia june april vaccine received emergency use authorization may vaccine received conditional marketing authorization united june vaccine received emergency use authorization chile vaccine provided via june malaysias national pharmaceutical regulatory agency npra issued conditional registration emergency use june janssen granted provisional approval july vaccine received provisional approval use people aged new august health family welfare minister india announced johnson johnson singledose vaccine approved emergency use india supply agreement homegrown vaccine maker biological e september national agency drug food control bpom issued emergency use authorization november vaccines authorization interim order canada transitioned approval use countrys food drug august vaccine janssen removed australian register therapeutic goods request janssencilag pty vaccine never supplied october fda cdc authorized use either homologous heterologous vaccine booster october us food drug administration fda centers disease control prevention cdc authorized use either homologous heterologous vaccine booster authorization expanded include adults november million doses janssen vaccine administered eueea authorization june given janssen vaccine single dose lower cost expected play important role low middleincome since single dose vaccine popular vaccine distribute refugee due fact difficult aforementioned demographics contacted vaccines require second dose lower costs lower requirements storage distribution comparison vaccines pfizer moderna janssen vaccine easily transported stored south african health minister zweli mkhize announced february country would sell swap one million doses astrazeneca south africa began vaccination using janssen vaccine february marking vaccines first use outside clinical july johnson johnson pledged deliver three hundred million doses vaccine us one hundred million upfront option twenty million deal worth billion funded biomedical advanced research development authority barda us department deal confirmed august johnson johnson signed contract us federal government billion agreeing deliver one hundred million doses vaccine us following food drug administration fda grant approval emergency use authorization eua agreement us government johnson johnson targeted produce twelve million doses end february sixty million doses end april one hundred million doses end june however january johnson johnson acknowledged manufacturing delays would likely prevent meeting contract twelve million doses delivered us end february congressional testimony company executive johnson johnson indicated company could deliver twenty million doses us government end march one hundred million doses first half february johnson johnson announced planned ship vaccine immediately following march canadian government placed order johnson johnson ten million doses option purchase twentyeight million march vaccine became fourth receive health canada shipments vaccine scheduled start second half april commitment deliver least two hundred million doses eu european distribution vaccine slightly delayed ema decided rare cases vaccineinduced blood clots outweigh benefits helping fight united states conference catholic bishops expressed concern vaccine cell line used development production originally derived retinal tissue fetus electively aborted although use fetal tissue vaccine development become common since especially cellbased vaccines currently alternatives carry potential ethical concerns janssen bioethicists dismiss ethical concerns using cells derived ethically compromised sources addressed alternatives others advance view cells used vaccines thousands generations removed source material contain fetal december vatican published note approved pope francis stating vaccinations recognized clinically safe effective used good conscience however key objection using vaccines still september criticism doses singleshot vaccine produced aspen pharmacares facility south africa exported europe millions doses shipped europe stored warehouses returned africa newly manufactured doses shipped african videos videosharing platforms circulated around may showing people magnets stick arms receiving vaccine purportedly demonstrating conspiracy theory vaccines contain microchips videos